Stockscreener 앱 받기
3.49
1.75%
0.06
시장 영업 전:
3.50
0.010
+0.29%
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
NRXP Stock Price, Quote & Chart - ChartMill
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Ithaca Journal
NRXP Should I Buy - Intellectia AI
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Zacks Research to Strong Sell - MarketBeat
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 - Investing.com
NRx Advances Ketamine Bid After FDA Review Clears Drug - MyChesCo
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRX (NRXP) Momentum: Ends Higher by 5.41% at $3.51 for the Current Session; the Current Price Sits Inside the Supplied Technical RangeIV Contraction - Vinanet
NRx cites arbitration in Kadima acquisition dispute - scanx.trade
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo Finance
Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum - TipRanks
NRx Pharmaceuticals Targets 2026 KETAFREE Approval, Advances DARPA-Backed Depression Trial - citybiz.co
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Cuts Target Price to $10 - moomoo.com
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
NRX Pharmaceuticals Q2 Results: EPS Misses Estimate, Sales Fall 94% - scanx.trade
NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand - TradingView
Five million ketamine doses are in production—but when can sales start? - Stock Titan
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to Be Held on Monday, August 17th at 4:30pm ET - Moomoo
NRX Pharmaceuticals earnings missed by $0.33, revenue fell short of estimates - Investing.com
NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates - FXStreet
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
NRX Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk - Stock Titan
NRX Pharmaceuticals Inc expected to post earnings of 6 cents a shareEarnings Preview - TradingView
NRXP Q2'26 Earnings: EPS estimate is (0.11) USD - TradingView
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy By Investing.com - Investing.com UK
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles - MarketBeat
Transcript : NRx Pharmaceuticals, Inc.Special Call - marketscreener.com
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy - Investing.com
NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Monday - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
NRx Advances FDA Review of Ketamine ANDA Packaging Issue - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - The Manila Times
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRx Pharmaceuticals completes FDA first-cycle ANDA review By Investing.com - Investing.com South Africa
NRx Pharmaceuticals to discuss FDA review and c... - Pluang
NRx Pharmaceuticals to Host Conference Call on FDA First-Cycle Review of Preservative-Free Ketamine ANDA - Quiver Quantitative
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference - GlobeNewswire
NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review - Moomoo
BTIG Research Cuts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $10.00 - MarketBeat
FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP) - FinancialContent
NRx Pharma rises on FDA review of ketamine ANDA (NRXP:NASDAQ) - Seeking Alpha
NRX Pharmaceuticals Inc. R (B1Q.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
NRx Pharmaceuticals completes FDA first-cycle ANDA review - Investing.com
FDA Completes First-Cycle Review of Preservative-Free - GlobeNewswire
Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Friday's After-Market SessionUniverse Pharmaceuticals (NASDAQ:UPC), BG - Benzinga
0.86%
0.31%
자본화:
|
볼륨(24시간):